Brief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
11/08/2026 14:01
BRIEF-Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US Aug 11 (Reuters) - Arch Biopartners Inc ARCH.V:
ARCH BIOPARTNERS TO EXPAND PHASE II CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY TRIAL TO THE UNITED STATES
ARCH BIOPARTNERS - NEW U.S. SITES EXPECTED TO REQUIRE FOUR TO SIX MONTHS FOR PREPARATION
ARCH BIOPARTNERS: CONTINUING TO GROW TRIAL IN CANADA AS ONE ADDITIONAL CANADIAN SITE MOVES THROUGH ACTIVATION PROCESS
Source text: ID:nGNX3Trmsw
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide